Skip to the answer

Lamotrigine

Lamotrigine is a seizure medicine (anticonvulsant) used to treat epilepsy in children and adults, and, in some immediate-release products, to help prevent mood episodes in bipolar I disorder.

Brand names LamictalLamictal CDLamictal OdtLamictal XrSubvenite
Drug classes Anti-epileptic Agent
Rx Forms 5
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026 Content updated Oct 2, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 123 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

✓No current FDA shortage listed · checked Oct 4, 2026
Lamotrigine at a glance The quick version — the full detail is in the Patient Information Guide below.
Dr. Brian Staiger, PharmD, BCPS
The Pharmacist’s Take By · Clinical pharmacist · Written

Lamotrigine (Lamictal) is a mainstay seizure medicine that also helps prevent new mood episodes in bipolar I disorder, likely by blocking sodium channels so overactive nerve cells settle down; it has been on the market since about 1994 and is available as a generic. Most people tolerate it well, with less weight gain and drowsiness than many mood stabilizers, though dizziness, headache, nausea or blurred or double vision can show up as the dose rises. Its boxed warning is for serious skin rash, including Stevens-Johnson syndrome, most often in the first 2 to 8 weeks, so stick exactly to the slow starting schedule and report any rash right away.

Clinical pearls

  • Never stop lamotrigine suddenly, even if you feel fine, because the label calls for a taper over at least 2 weeks.
  • Valproate (divalproex) more than doubles lamotrigine levels and raises rash risk, so the starting schedule must be much slower with it.
  • Estrogen birth control cuts lamotrigine levels about in half, so tell your prescriber before starting or stopping it.
  • Swallow extended-release tablets (Lamictal XR) whole, and never chew, crush or split them.
How we write & review this content — our editorial policy →
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾

Lamotrigine can cause serious, life-threatening skin rashes. Stop it and contact your doctor at the first sign of any rash, unless a doctor confirms it is clearly not from the drug.

These rashes include Stevens-Johnson syndrome and toxic epidermal necrolysis. They are more common in children than in adults. Risk is higher with valproate, a starting dose that is too high, increasing the dose too fast, or the HLA-B*1502 gene variant. Most serious rashes appear within 2 to 8 weeks, but some occur later. Doctors can't tell which rashes will turn serious, and stopping may not prevent a rash from worsening.

Read the full warning on DailyMed →
How you get itPrescription only
Comes asTablet, Extended-release tablet, Orally disintegrating tablet +2
Earliest FDA record1995
Companies listing it with the FDA46
FDA label last updatedOct 10, 2025
FDA’s strongest warning (boxed)Yes, read the warning

Patient information guide A plain-language walkthrough of Lamotrigine, written from its FDA label.

What Lamotrigine is used for

▾

Lamotrigine is used for epilepsy and, in some products, bipolar I disorder.

  • Lamictal, Subvenite, and lamotrigine tablets, chewable tablets and orally disintegrating tablets: add-on therapy for partial-onset seizures, primary generalized tonic-clonic seizures and Lennox-Gastaut syndrome seizures, ages 2 and older.
  • These same products: switching to lamotrigine alone in partial-onset seizures from carbamazepine, phenytoin, phenobarbital, primidone or valproate, ages 16 and older.
  • These same products: maintenance treatment of bipolar I disorder to delay mood episodes. Not recommended for acute manic or mixed episodes.
  • Lamictal XR and lamotrigine extended-release tablets: add-on therapy for primary generalized tonic-clonic and partial-onset seizures, ages 13 and older.
  • Extended-release products: switching to monotherapy in partial-onset seizures, ages 13 and older. They are not labeled for bipolar disorder.

How Lamotrigine works

▾

The exact way lamotrigine works is unknown. It may block voltage-sensitive sodium channels, which steadies nerve cell membranes and reduces release of excitatory chemicals like glutamate. Its action in bipolar disorder has not been established.

Lamotrigine dosage

▾

Lamotrigine is taken by mouth. Dosing depends on your other medicines, your condition and your age, with slow step-ups to lower rash risk. Starter kits cover the first 5 weeks for some products.

  • Extended-release tablets are taken once a day, with or without food, and swallowed whole.
  • Food does not change how well it is absorbed.
  • Taper over at least 2 weeks when stopping.
  • Follow your label and prescriber for missed doses.

Dosing details from the FDA-approved label

From the Lamotrigine prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.

  • Discontinuation
    • Taper over a period of at least 2 weeks (approximately 50% dose reduction per week)
  • Women taking estrogen-containing oral contraceptives (not taking carbamazepine, phenytoin, phenobarbital, primidone, rifampin, lopinavir/ritonavir or atazanavir/ritonavir) - maintenance dose
    • The maintenance dose will in most cases need to be increased by as much as 2-fold over the recommended target maintenance dose to maintain a consistent lamotrigine plasma level
  • Starting estrogen-containing oral contraceptives in women on a stable dose of SUBVENITE (not taking the inducers listed above)
    • Maintenance dose will in most cases need to be increased by as much as 2-fold
    • Increases begin when the oral contraceptive is introduced and continue, based on clinical response, no more rapidly than 50 to 100 mg/day every week
    • Dose increases should not exceed the recommended rate unless plasma levels or clinical response support larger increases.
  • Women taking SUBVENITE in addition to carbamazepine, phenytoin, phenobarbital, primidone, rifampin, lopinavir/ritonavir or atazanavir/ritonavir
    • No adjustment to the dose of SUBVENITE should be necessary
  • Lamotrigine Extended-Release Tablets administration
    • Taken once daily, with or without food
    • Tablets must be swallowed whole and must not be chewed, crushed, or divided
Read the label’s full dosing text

2 DOSAGE AND ADMINISTRATION Dosing is based on concomitant medications, indication, and patient age. ( 2.1 , 2.2 , 2.3 , 2.4 ) To avoid an increased risk of rash, the recommended initial dose and subsequent dose escalations should not be exceeded ( 2.1 , 16 ) Do not restart lamotrigine tablets in patients who discontinued due to rash unless the potential benefits clearly outweigh the risks. ( 2.1 , 5.1 ) Adjustments to maintenance doses will be necessary in most patients starting or stopping estrogen-containing oral contraceptives. ( 2.1 , 5.9 ) Discontinuation: Taper over a period of at least 2 weeks (approximately 50% dose reduction per week). ( 2.1 , 5.10 ) Epilepsy Adjunctive therapy—See Table 1 for patients older than 12 years and Tables 2 and 3 for patients aged 2 to 12 years. ( 2.2 ) Conversion to monotherapy—See Table 4. ( 2.3 ) Bipolar disorder: See Tables 5 and 6. ( 2.4 ) 2.1 General Dosing Considerations Rash There are suggestions, yet to be proven, that the risk of severe, potentially life threatening rash may be increased by (1) coadministration of lamotrigine tablets with valproate, (2) exceeding the recommended initial dose of lamotrigine tablets, or (3) exceeding the recommended dose escalation for lamotrigine tablets. However, cases have occurred in the absence of these factors [ see Boxed Warning ] . Therefore, it is important that the dosing recommendations be followed closely. The risk of nonserious rash may be increased when the recommended initial dose and/or the rate of dose escalation for lamotrigine tablets is exceeded and in patients with a history of allergy or rash to other AEDs. It is recommended that lamotrigine tablets not be restarted in patients who discontinued due to rash associated with prior treatment with lamotrigine unless the potential benefits clearly outweigh the risks. If the decision is made to restart a patient who has discontinued lamotrigine tablets, the need to restart with the initial dosing recommendations should be assessed. The greater the interval of time since the previous dose, the greater consideration should be given to restarting with the initial dosing recommendations. If a patient has discontinued lamotrigine for a period of more than 5 half-lives, it is recommended that initial dosing recommendations and guidelines be followed.

Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →

Lamotrigine side effects

▾

Common side effects include:

Common side effects

  • Dizziness
  • Headache
  • Double vision or blurred vision
  • Poor coordination or unsteadiness (ataxia)
  • Nausea or vomiting
  • Sleepiness
  • Runny nose or sore throat
  • Rash

When to get medical help

  • Get help right away if you develop any skin rash. Lamotrigine can cause life-threatening rashes, including Stevens-Johnson syndrome.
  • Call your doctor right away for fever, swollen glands or signs of a multiorgan allergic reaction (DRESS), even without a rash.
  • Seek urgent care for signs of severe systemic inflammation, such as fever, rash and organ problems (hemophagocytic lymphohistiocytosis, or HLH).
  • Report unusual bruising or bleeding, unexpected infections or signs of anemia. These can be blood problems.
  • Report headache, fever and nausea, which may signal aseptic meningitis (irritation of the brain's lining not caused by infection).
  • Tell your doctor right away about new or worsening depression, unusual mood changes or thoughts of self-harm.
  • Seek help for a racing, irregular or abnormal heartbeat, especially if you have heart disease.
  • Don't stop suddenly, because withdrawal seizures can occur.

Lamotrigine warnings and precautions

▾

Serious skin rash is the biggest risk. Report any rash immediately. Children, people taking valproate, and those who go up in dose too fast are at higher risk.

  • Multiorgan allergic reaction (DRESS) and HLH
  • Blood disorders
  • Aseptic meningitis
  • Dangerous heart rhythms in people with heart disease
  • Increased risk of suicidal thoughts
  • Withdrawal seizures if stopped suddenly

Lamotrigine interactions

▾

Several medicines change lamotrigine levels.

  • Valproate: more than doubles levels and raises rash risk.
  • Carbamazepine, phenytoin, phenobarbital, primidone, rifampin: lower levels by about 40%.
  • Estrogen-containing birth control: lowers levels by about 50%.
  • Lopinavir/ritonavir and atazanavir/ritonavir: lower levels.
  • Dofetilide: combination not recommended.

Interactions listed in the FDA-approved label

From the Lamotrigine prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Valproate: Increases lamotrigine concentrations slightly more than 2-fold (inhibits glucuronidation); conflicting data on lamotrigine's effect on valproate concentrations. See dosing guidance in Dosage and Administration (Tables 1, 2, 5 to 6, 13).
  • Carbamazepine: Decreases lamotrigine concentration approximately 40%; may increase carbamazepine epoxide levels.
  • Phenytoin: Decreases lamotrigine concentration approximately 40%.
  • Phenobarbital/primidone: Decreases lamotrigine concentration approximately 40%.
  • Rifampin: Decreases lamotrigine AUC approximately 40%.
  • Estrogen-containing oral contraceptives (30 mcg ethinylestradiol and 150 mcg levonorgestrel): Decrease lamotrigine concentrations approximately 50% and decrease the levonorgestrel component by 19%. Maintenance dose adjustments are needed in most patients starting or stopping estrogen-containing products (see Dosage and Administration 2.1 and Warnings 5.9).
  • Lopinavir/ritonavir: Decreases lamotrigine concentration approximately 50%.
  • Atazanavir/ritonavir: Decreases lamotrigine AUC approximately 32%.
  • Organic cationic transporter 2 (OCT2) substrates with a narrow therapeutic index (e.g., dofetilide): Lamotrigine inhibits renal tubular secretion via OCT2, which may increase plasma levels of drugs excreted by this route. Coadministration is not recommended.
Read the label’s full interactions text

7 DRUG INTERACTIONS Significant drug interactions with lamotrigine are summarized in this section. Uridine 5´-diphospho-glucuronyl transferases (UGT) have been identified as the enzymes responsible for metabolism of lamotrigine. Drugs that induce or inhibit glucuronidation may, therefore, affect the apparent clearance of lamotrigine. Strong or moderate inducers of the cytochrome P450 3A4 (CYP3A4) enzyme, which are also known to induce UGT, may also enhance the metabolism of lamotrigine. Those drugs that have been demonstrated to have a clinically significant impact on lamotrigine metabolism are outlined in Table 13. Specific dosing guidance for these drugs is provided in the Dosage and Administration section, and, for women taking estrogen-containing products, including oral contraceptives, in the Warnings and Precautions section [see Dosage and Administration (2.1) , Warnings and Precautions (5.9) ] . Additional details of these drug interaction studies are provided in the Clinical Pharmacology section [see Clinical Pharmacology (12.3) ] . Table 13. Established and Other Potentially Significant Drug Interactions ↓ = Decreased (induces lamotrigine glucuronidation). ↑ = Increased (inhibits lamotrigine glucuronidation). ? = Conflicting data. Concomitant Drug Effect on Concentration of Lamotrigine or Concomitant Drug Clinical Comment Estrogen-containing oral contraceptive preparations containing 30 mcg ethinylestradiol and 150 mcg levonorgestrel ↓ lamotrigine Decreased lamotrigine concentrations approximately 50%. ↓ levonorgestrel Decrease in levonorgestrel component by 19%. Carbamazepine and carbamazepine epoxide ↓ lamotrigine Addition of carbamazepine decreases lamotrigine concentration approximately 40%. ? carbamazepine epoxide May increase carbamazepine epoxide levels. Lopinavir/ritonavir ↓ lamotrigine Decreased lamotrigine concentration approximately 50%. Atazanavir/ritonavir ↓ lamotrigine Decreased lamotrigine AUC approximately 32%.

Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

🌿116 supplements and herbs with documented Lamotrigine interactions, ranked by severity Check Lamotrigine against a supplement or herb →

Before taking Lamotrigine

▾
  • Don't use if allergic to lamotrigine or its ingredients.
  • Mention prior rash or allergy to seizure medicines.
  • Mention heart disease.
  • Tell your doctor if pregnant, planning pregnancy or breastfeeding.
  • Liver or kidney impairment may need dose adjustments.
  • Age limits apply by product.

Lamotrigine overdose

▾

Overdoses, some fatal, have caused unsteadiness, abnormal eye movements, seizures, reduced consciousness, coma and heart conduction delay. There is no specific antidote. Seek emergency care and contact Poison Control.

What Lamotrigine does in the body

▾

In lab studies, lamotrigine blocked sodium channels and lowered folate levels by inhibiting an enzyme called dihydrofolate reductase. It also acts like a Class IB antiarrhythmic on heart sodium channels. In people with significant heart disease, it could slow heart conduction and cause dangerous rhythms.

How your body processes Lamotrigine

▾

Lamotrigine is rapidly and almost completely absorbed, and food doesn't affect it. Peak levels come about 1.4 to 4.8 hours after a dose. It is about 55% bound to plasma proteins and is broken down mainly by glucuronidation. Most is eliminated in urine. Its half-life varies with other medicines, such as valproate (longer) or carbamazepine (shorter).

How to store Lamotrigine

▾

Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) in a dry place. Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) in a dry place and protect from light.

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

116

Supplements & herbs that interact with Lamotrigine

116 supplements and herbal products have documented interactions with Lamotrigine in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.

Severity mix
  • Major · 7
  • Moderate · 92
  • Minor · 17
1,4-BUTANEDIOL Major ACTIVATED CHARCOAL Major BEER Major GAMMA-HYDROXYBUTYRATE (GHB) Major KAVA Major L-TRYPTOPHAN Major WINE Major 5-HTP Moderate +108 more
Every supplement checked against Lamotrigine — ranked by severity The full interaction hub: 7 major · 92 moderate · 17 minor · every one linked to its full report. Check Lamotrigine against your exact supplements

Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

1

Nutrient depletion considerations

Lamotrigine has been associated with lower levels of 1 nutrient in the clinical literature. This does not mean a deficiency will occur — it means these may be worth discussing with your pharmacist or healthcare provider, especially with long-term use.

VITAMIN K Insignificant Depletion
See the full Lamotrigine nutrient depletion report

Educational information from a licensed clinical database (Natural Medicines) — not medical advice. Do not start or stop medications or supplements without professional guidance.

Lamotrigine: pharmacist answers to common questions

Quick, plain-English answers to the questions patients ask most about Lamotrigine — the kind of thing our pharmacy team would talk through with you at the counter.

What is lamotrigine for?

▾
It treats epilepsy, helping control certain seizure types. Some forms, like tablets, chewables and orally disintegrating tablets, are also used to delay mood episodes in bipolar I disorder. Extended-release versions are for epilepsy only.

Why is rash such a big deal?

▾
Lamotrigine can cause serious, even life-threatening skin reactions, mostly in the first 2 to 8 weeks. We can't tell which rashes are dangerous, so call your doctor right away about any rash. Don't try to wait it out.

How should I take it?

▾
Take it by mouth exactly as prescribed, increasing slowly as planned. Skipping ahead raises rash risk. Extended-release tablets are once daily and must be swallowed whole. Food doesn't matter.

Can I stop it if I feel fine?

▾
Please don't stop on your own. Stopping suddenly can trigger withdrawal seizures. Your doctor will taper you off over at least 2 weeks.

Do my other medicines matter?

▾
Yes. Valproate raises lamotrigine levels and rash risk. Carbamazepine, phenytoin and rifampin lower them. Estrogen birth control also lowers them, so your dose may need adjusting. Tell me about everything you take.

What if I'm pregnant or plan to be?

▾
Talk to your doctor. Registry data haven't shown a higher overall rate of major birth defects. Doses may need adjusting during pregnancy and after delivery. Don't stop it on your own if you have epilepsy.

Is Lamotrigine available over the counter?

▾
No. Lamotrigine is a prescription medicine: every Lamotrigine product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was Lamotrigine first available?

▾
The earliest FDA record we hold for Lamotrigine is from 1995: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when Lamotrigine was first used.

Who makes Lamotrigine?

▾
46 companies currently list Lamotrigine products in the FDA's NDC Directory, including GlaxoSmithKline LLC, Remedyrepack Inc., Par Health USA, LLC. That count includes repackagers and distributors as well as manufacturers (companies that sell only the raw ingredient are not counted), so fewer companies actually make it; the label on your bottle names the one that supplied yours.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

More about Lamotrigine on HelloPharmacist

📊Lamotrigine supplement interactions116 checked — ranked by severity 🌿Drug & Supplement CheckerLamotrigine vs. vitamins & herbs 💬Ask a PharmacistFree answer, usually < 24h 🔎NDC & pricing lookupFind Lamotrigine NDCs & costs 🅰️Browse Drugs A–ZLook up any medication
Detailed data & references for Lamotrigine Forms & strengths, pricing, billing codes, manufacturers, safety reports and sourcing — the data behind the page. Most people can stop here. Each section below opens on a tap.

Lamotrigine forms and strengths (how it comes)

Lamotrigine is available in 5 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Tablet

By mouth
Brands Lamictal Subvenite
How this form is used
What it may be used for
  • Lamictal and Subvenite tablets are used for epilepsy and for bipolar I maintenance treatment.
  • Lamotrigine Extended Release tablets are used for epilepsy in ages 13 and older.
Important instructions
  • Lamictal Starter Kits and Subvenite Starter Kits are available for the first 5 weeks of treatment.
  • Lamotrigine Extended Release tablets are taken once daily and swallowed whole.
Available strengths 9 strengths
2 mg 5 mg 25 mg 50 mg 100 mg 150 mg
Show 3 more strengths Show fewer strengths
200 mg 250 mg 300 mg
405 FDA-listed product records ⓘ

Extended-release tablet

By mouth
Brands Lamictal
How this form is used
What it may be used for
  • Lamictal XR is used as add-on therapy for primary generalized tonic-clonic and partial-onset seizures in ages 13 and older.
  • Lamictal XR is used to convert to monotherapy in partial-onset seizures in ages 13 and older.
  • Lamotrigine ER is not established for children under 13.
Important instructions
  • Lamotrigine ER tablets are taken once daily, with or without food.
  • Lamotrigine ER tablets must be swallowed whole, not chewed, crushed or divided.
Available strengths 6 strengths
25 mg 50 mg 100 mg 200 mg 250 mg 300 mg
187 FDA-listed product records ⓘ

Orally disintegrating tablet

By mouth
Brands Lamictal
How this form is used
What it may be used for
  • Lamotrigine orally disintegrating tablets are used for epilepsy add-on therapy in ages 2 and older.
  • Lamotrigine orally disintegrating tablets are used for bipolar I maintenance treatment.
Important instructions
  • Lamictal ODT Patient Titration Kits are available for the first 5 weeks of treatment.
Available strengths 4 strengths
25 mg 50 mg 100 mg 200 mg
84 FDA-listed product records ⓘ

Chewable tablet

By mouth
How this form is used
What it may be used for
  • Lamotrigine chewable tablets are used for epilepsy add-on therapy in ages 2 and older.
  • Lamotrigine chewable tablets are used to convert to monotherapy in partial-onset seizures in ages 16 and older.
  • Lamotrigine chewable tablets are used for bipolar I maintenance treatment.
Important instructions
  • Lamotrigine chewable tablets are labeled as chewable, dispersible tablets.
Available strengths 2 strengths
5 mg 25 mg
32 FDA-listed product records ⓘ

Oral suspension

By mouth
Brands Subvenite
How this form is used
What it may be used for
  • Subvenite oral suspension is used for epilepsy add-on therapy in ages 2 and older.
  • Subvenite oral suspension is used for bipolar I maintenance treatment.
Important instructions
  • Subvenite oral suspension dosing depends on other medicines, condition and age.
Available strengths 1 strength
10 mg/mL
1 FDA-listed product record ⓘ

Lamotrigine on the U.S. market: products, makers and brands

How Lamotrigine appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

46 companies list 300 Lamotrigine product records with the FDA, mostly as tablet, extended-release tablet, orally disintegrating tablet; the earliest marketing or approval year on record is 1995. Brand names on the directory include Lamictal, Lamictal CD, Lamictal Odt and 2 more; the rest are generics.

5
Dose forms ⓘ
46
Labelers (makers, repackagers, distributors)
9
Brand names
300
FDA-listed product records ⓘ
1995
Earliest FDA record ⓘ

FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

Also listed with the FDA, not a patient dose form: Kit (52) · Powder (21) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.

GlaxoSmithKline LLC8%
Remedyrepack Inc.5%
Par Health USA, LLC5%
Zydus Pharmaceuticals USA Inc.5%
Alembic Pharmaceuticals Inc.4%
Alembic Pharmaceuticals Limited4%
Other makers69%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

How widely Lamotrigine is used (Medicaid data)

A general measure of how commonly Lamotrigine is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Lamotrigine is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

4,467,083
Medicaid prescriptions filled (Q1–Q4 2025)
$128.7M gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Lamotrigine prescribed? Of the 1,601 medications we measure, Lamotrigine ranks #47 by Medicaid prescriptions — more than 97% of them.

Where Lamotrigine ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5
Total prescriptions — #47 of 1,601
#42 Buspirone 5,180,004 Rx #43 Aripiprazole 5,031,681 Rx #44 Diclofenac Topical (ar... 4,673,607 Rx #45 Diclofenac Topical (ac... 4,673,607 Rx #46 Diclofenac 4,673,607 Rx #47 Lamotrigine 4,467,083 Rx #48 Cyclobenzaprine 4,437,147 Rx #49 Triamcinolone Topical 4,329,207 Rx #50 Duloxetine 4,105,865 Rx #51 Methadone 4,056,849 Rx #52 Guanfacine 4,043,576 Rx

Utilization by Lamotrigine product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

The 100 mg oral tablet is the most-dispensed Lamotrigine product — about 30% of these Medicaid prescriptions.

lamotrigine 100 MG Oral Tablet Most dispensed

1,327,623 Medicaid prescriptions (Q1–Q4 2025) 30% of Lamotrigine prescriptions shown $21M gross reimbursement (before rebates) ≈ $16 per prescription (gross)

Summed across the 21 of 131 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 198427

lamotrigine 25 MG Oral Tablet

1,192,244 Medicaid prescriptions (Q1–Q4 2025) 27% of Lamotrigine prescriptions shown $15.9M gross reimbursement (before rebates) ≈ $13 per prescription (gross)

Summed across the 20 of 123 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 282401

lamotrigine 200 MG Oral Tablet

935,774 Medicaid prescriptions (Q1–Q4 2025) 21% of Lamotrigine prescriptions shown $19.8M gross reimbursement (before rebates) ≈ $21 per prescription (gross)

Summed across the 18 of 98 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 198429

lamotrigine 150 MG Oral Tablet

606,044 Medicaid prescriptions (Q1–Q4 2025) 14% of Lamotrigine prescriptions shown $10.8M gross reimbursement (before rebates) ≈ $18 per prescription (gross)

Summed across the 18 of 115 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 198428

24 HR lamotrigine 200 MG Extended Release Oral Tablet

84,720 Medicaid prescriptions (Q1–Q4 2025) 2% of Lamotrigine prescriptions shown $15.6M gross reimbursement (before rebates) ≈ $184 per prescription (gross)

Summed across the 8 of 34 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 900156

24 HR lamotrigine 100 MG Extended Release Oral Tablet

63,577 Medicaid prescriptions (Q1–Q4 2025) 1% of Lamotrigine prescriptions shown $7.4M gross reimbursement (before rebates) ≈ $116 per prescription (gross)

Summed across the 8 of 29 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 850087

24 HR lamotrigine 50 MG Extended Release Oral Tablet

55,148 Medicaid prescriptions (Q1–Q4 2025) 1% of Lamotrigine prescriptions shown $4.6M gross reimbursement (before rebates) ≈ $83 per prescription (gross)

Summed across the 9 of 38 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 850091

24 HR lamotrigine 300 MG Extended Release Oral Tablet

53,428 Medicaid prescriptions (Q1–Q4 2025) 1% of Lamotrigine prescriptions shown $10.4M gross reimbursement (before rebates) ≈ $195 per prescription (gross)

Summed across the 8 of 39 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1098608

lamotrigine 25 MG Tablet for Oral Suspension

42,422 Medicaid prescriptions (Q1–Q4 2025) <1% of Lamotrigine prescriptions shown $4.2M gross reimbursement (before rebates) ≈ $99 per prescription (gross)

Summed across the 5 of 29 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 311264

24 HR lamotrigine 250 MG Extended Release Oral Tablet

28,676 Medicaid prescriptions (Q1–Q4 2025) <1% of Lamotrigine prescriptions shown $4.8M gross reimbursement (before rebates) ≈ $167 per prescription (gross)

Summed across the 8 of 29 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1146690

24 HR lamotrigine 25 MG Extended Release Oral Tablet

16,844 Medicaid prescriptions (Q1–Q4 2025) <1% of Lamotrigine prescriptions shown $811,758 gross reimbursement (before rebates) ≈ $48 per prescription (gross)

Summed across the 9 of 30 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 900164

lamotrigine 50 MG Disintegrating Oral Tablet

16,729 Medicaid prescriptions (Q1–Q4 2025) <1% of Lamotrigine prescriptions shown $3.2M gross reimbursement (before rebates) ≈ $193 per prescription (gross)

Summed across the 6 of 22 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 252478

lamotrigine 100 MG Disintegrating Oral Tablet

16,510 Medicaid prescriptions (Q1–Q4 2025) <1% of Lamotrigine prescriptions shown $4.8M gross reimbursement (before rebates) ≈ $292 per prescription (gross)

Summed across the 6 of 23 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 103968

lamotrigine 5 MG Tablet for Oral Suspension

10,903 Medicaid prescriptions (Q1–Q4 2025) <1% of Lamotrigine prescriptions shown $346,033 gross reimbursement (before rebates) ≈ $32 per prescription (gross)

Summed across the 4 of 32 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 311265

lamotrigine 200 MG Disintegrating Oral Tablet

8,050 Medicaid prescriptions (Q1–Q4 2025) <1% of Lamotrigine prescriptions shown $2.2M gross reimbursement (before rebates) ≈ $276 per prescription (gross)

Summed across the 6 of 22 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 252479

lamotrigine 25 MG Disintegrating Oral Tablet

7,441 Medicaid prescriptions (Q1–Q4 2025) <1% of Lamotrigine prescriptions shown $2.2M gross reimbursement (before rebates) ≈ $294 per prescription (gross)

Summed across the 6 of 24 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 198430

Other Lamotrigine products — combination packs and listings not yet matched to a specific clinical product (kept visible so every prescription is accounted for)

950 Medicaid prescriptions (Q1–Q4 2025) <1% of Lamotrigine prescriptions shown $630,675 gross reimbursement (before rebates) ≈ $664 per prescription (gross)

Summed across the 5 of 150 listed NDC products with Medicaid activity.

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Lamotrigine, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 165 of 968 listed Lamotrigine NDCs with Medicaid activity.

Compare Lamotrigine products

A representative set of FDA-listed product records for Lamotrigine — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Showing 79 of 300 products — FDA National Drug Code Directory. See every product, package size and price: browse all 300 Lamotrigine NDCs →

Lamotrigine recall history

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list one Lamotrigine recall since July 2021. It is no longer listed as ongoing. A recall names specific lots from one company, so check the lot number on your own bottle rather than assuming every product is affected; your pharmacist can check whether your supply came from an affected lot.

Class III Jul 20, 2022 · Terminated · AVKARE Inc.
Labeling: Label Error on Declared Strength
  • Lamotrigine Tablets, USP 100 mg, 1000-count bottles, Rx Only, Manufactured for: AvKARE, Inc. Pulaski, TN 38478, NDC 42291-367-10, UPC 3 42291 36710 4 Lots: Lot #: 42581 Exp. 12/2024; 42484 Exp. 11/2024; 41204 Exp. 05/2024; 38723 Exp. 02/2023; 37623 Exp. 10/2022 FDA record D-1329-2022 →

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.

RxNorm Concept Web — From Ingredient to Every Form and Strength

This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.

Ingredient (IN) Lamotrigine RxCUI 28439 5 dose forms · 21 strengths
  1. Dose form (SCDF) Disintegrating Oral Tablet RxCUI 372566 In current FDA listings
    Clinical drug / strength (SCD) 25 MG RxCUI 198430 50 MG RxCUI 252478 100 MG RxCUI 103968 200 MG RxCUI 252479
  3. Dose form (SCDF) Oral Suspension RxCUI 2724461 In current FDA listings
    Clinical drug / strength (SCD) 10 MG/ML RxCUI 2724462
  4. Dose form (SCDF) Oral Tablet RxCUI 372567 In current FDA listings
    Clinical drug / strength (SCD) 2 MG RxCUI 391875 25 MG RxCUI 282401 50 MG RxCUI 199322 100 MG RxCUI 198427 150 MG RxCUI 198428 200 MG RxCUI 198429 250 MG RxCUI 249329
  5. Dose form (SCDF) Tablet for Oral Suspension RxCUI 2697774 In current FDA listings
    Clinical drug / strength (SCD) 2 MG RxCUI 349010 5 MG RxCUI 311265 25 MG RxCUI 311264

Look up RxCUI 28439 in the RxCUI Atlas →

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

💵 What Lamotrigine costs pharmacies (NADAC benchmark)

The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.

FormStrengthPharmacy acquisition benchmark
Tablet · Oral 100 mg $10.92 per tablet NDC details & price history
Tablet · Oral 25 mg $10.30 per tablet NDC details & price history
Tablet · Oral 200 mg $12.05 per tablet NDC details & price history
Tablet · Oral 150 mg $11.47 per tablet NDC details & price history
Tablet · Oral 50 mg $1.27 per tablet NDC details & price history
Tablet · Oral 250 mg $1.30 per tablet NDC details & price history
Tablet · Oral 300 mg $1.26 per tablet NDC details & price history
Tablet, Film Coated, Extended Release · Oral 200 mg $32.33 per tablet NDC details & price history
Tablet, Film Coated, Extended Release · Oral 250 mg $44.21 per tablet NDC details & price history
Tablet, Film Coated, Extended Release · Oral 300 mg $48.65 per tablet NDC details & price history
Why show this? Your out-of-pocket cost depends on insurance, pharmacy markup, and discounts — but the acquisition benchmark tells you whether the medication itself is inexpensive or costly, which strengths cost more per dose, and whether a cash-price quote is in a reasonable range. Each row links to the NDC-level record with its full price history.

Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.

Lamotrigine brand names

Lamotrigine is sold under 5 brand names in the FDA directory — Lamictal, Lamictal CD, Lamictal Odt, Lamictal Xr and others. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.

Lamictal Lamictal CD Lamictal Odt Lamictal Xr Subvenite

Who makes Lamotrigine: manufacturers and labelers

46 companies list Lamotrigine products with the FDA. By number of product records, the largest are GlaxoSmithKline LLC, Remedyrepack Inc., Par Health USA, LLC. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

GlaxoSmithKline LLC 25 Remedyrepack Inc. 15 Par Health USA, LLC 14 Zydus Pharmaceuticals USA Inc. 14 Alembic Pharmaceuticals Inc. 13 Alembic Pharmaceuticals Limited 13 Dr.Reddy's Laboratories Limited 12 Torrent Pharmaceuticals Limited 12 OWP Pharmaceuticals, Inc. 11 AvKARE 10 Bryant Ranch Prepack 10 NorthStar Rx LLC 10 Amneal Pharmaceuticals of New York LLC 8 Sun Pharmaceutical Industries, Inc. 8 Zydus Lifesciences Limited 8 A-S Medication Solutions 6 Amneal Pharmaceuticals LLC 6 Aurobindo Pharma Limited 6 Camber Pharmaceuticals Inc 6 Yiling Pharmaceutical, Inc. 6 Proficient Rx LP 5 Actavis Pharma, Inc. 4 Advagen Pharma Limited 4 Ajanta Pharma USA Inc. 4

…and 22 more on the FDA NDC directory.

Lamotrigine drug class (RxNorm)

Lamotrigine belongs to the Mood Stabilizer class.

Pharmacologic class Mood Stabilizer, Anti-epileptic Agent
Drug family (ATC) Other antiepileptics
How it works Dihydrofolate Reductase Inhibitors, Organic Cation Transporter 2 Inhibitors

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

Sources for this Lamotrigine page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective Oct 10, 2025
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Lamotrigine.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Lamotrigine after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
123
Finished products in the current FDA directory
300
Companies listing them (makers, repackagers, distributors)
46
FDA labeler codes behind them ⓘ
53
Linked representative label ⓘ
GlaxoSmithKline LLC
Linked label effective
Oct 10, 2025
Composite sections available
24
Linked SPL Set ID
d7e3572d-56fe-4727-2bb4-013ccca22678
Linked SPL Document ID
4492fd3c-e068-4599-8a10-0b26ea2a4f91
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. GlaxoSmithKline LLC is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →